EDMedix describes the professional qualifications, responsibilities and attribution standards that apply when a real healthcare professional reviews our erectile dysfunction medication information. This page explains the reviewer role and how an actual review should be documented. It does not present an invented physician or claim universal clinical sign-off.
Last updated: October 15, 2026
A medical reviewer evaluates the clinical meaning, safety implications and evidentiary support of an article. In ED medication content, that may include approved indications, contraindications, serious side effects, interactions, study endpoints and risks associated with misunderstanding drug formulations.
This is distinct from grammar editing or routine citation checking. The Medical Review Policy explains how the two activities should complement one another.
Any named EDMedix reviewer should be a real healthcare professional who has actually evaluated the specific content being credited. We do not create fabricated biographies, use stock photographs as medical identities or attribute an article to a physician without documented permission.
When a professional review is genuinely completed, attribution may describe the reviewer’s name, professional designation, relevant jurisdiction or license, expertise, actual role and date. Unsupported credentials should not appear on the site.
A physician with relevant clinical experience may assess ED evaluation, cardiovascular suitability and treatment context. A licensed pharmacist with appropriate competence may review medication labels, interactions, dosage-form equivalence and pharmacy safety. The qualification must match the claim being reviewed.
A professional designation is not a universal credential for every specialist subject. Knowledge of urology, primary care, cardiovascular medication management or clinical pharmacology should be asserted only where supported.
| Qualification area | Why it matters |
|---|---|
| Medical or pharmacy degree | Foundational preparation for clinical interpretation |
| Professional license where relevant | Checkable authorization and standing |
| Experience with ED and drug safety | Relevant to PDE5 contraindications and outcomes |
| Evidence appraisal | Ability to interpret trial design, endpoints and limitations |
| Product-label familiarity | Ability to distinguish FDA-approved formulations and instructions |
| Conflicts disclosure | Helps identify potential commercial influence |
Professional identity can be evaluated through official state licensing databases, recognized certification bodies, current institutional profiles or suitable primary records. An academic degree does not prove that a professional currently holds a license.
A reviewer credit should not be displayed when professional status or consent cannot be established. For a completed review, EDMedix should retain an internal record of who reviewed the content and what was covered.
| Claim | Suitable verification |
|---|---|
| Professional identity | Identifiable individual and consent to attribution |
| State licensure | Official state medical or pharmacy licensing board |
| Specialty certification | Relevant maintained professional registry |
| Academic credential | Verified academic or authorized professional record |
| Current institutional affiliation | Institutional source when available |
| Article review | Record identifying page, content version and review date |
Review may cover accuracy of the active ingredient, U.S. regulatory status, labeled strengths, route, contraindications, interactions, warnings and whether statements encourage inappropriate self-treatment. It may also evaluate how well uncertainty is communicated.
It does not certify a pharmacy’s inventory, authenticate an overseas package or prove that a generic product is FDA approved without relevant regulatory records.
High-priority issues include sildenafil and nitrates, tadalafil interactions, vardenafil interactions, vardenafil ODT and ED medication adverse effects. Injectable alprostadil information additionally requires care with product systems, training and priapism warnings.
Having these topics in the editorial plan does not establish that a reviewer has already signed off on them. Completed review should be documented for each article or clearly defined content scope.
A sentence can match a published source but still mislead if its context is omitted. For example, an observed effect eight hours after a drug in one study does not become a guaranteed eight-hour response for all patients; a 36-hour tadalafil study window does not mean a continuous erection.
A reviewer should check that clinical language does not confuse pharmacokinetics with actual patient outcomes or imply stronger claims than the evidence supports.
Viagra and corresponding sildenafil ED generics require product-specific checks. Cialis has separate as-needed, daily ED and BPH contexts. Vardenafil conventional tablets and 10 mg ODT are not interchangeable merely because the number on the label matches.
For injection therapy, Caverject, Caverject Impulse and Edex have different handling and device considerations. A qualified reviewer should flag dangerous simplifications or unsupported substitution claims.
Company catalogs describing India-market brands can be useful to identify names, claimed ingredient contents and variants, but they do not establish FDA approval or guarantee that a third-party package is authentic.
Brands containing a second drug, such as dapoxetine combinations, require explicit distinction from single-ingredient sildenafil, tadalafil or vardenafil. Medical review should prevent editorial shorthand from concealing a second active ingredient.
A reviewer should disclose material financial or professional relationships that could reasonably influence a judgment about the subject. A retailer or manufacturer should not be allowed to dictate contraindication language, erase uncertainty or guarantee treatment results.
EDMedix has a separate Affiliate Disclosure because referral compensation and professional medical validation are not interchangeable trust signals.
The writer prepares and documents an article; the clinician evaluates specified clinical aspects when a review actually occurs. A person may contribute in both capacities, but the roles should be accurately stated rather than inferred from a general biography.
Authorship, editorial updates, regulatory source checking and completed independent professional review should not be collapsed into a single unverified “medically approved” label.
A completed clinical review should have a recorded date and relate to an identifiable content version. Significant changes to warnings, dosages, regulatory status or study interpretation can warrant renewed review instead of automatically carrying forward an earlier credit.
Routine fixes to spelling or links may have different implications. The review record should distinguish those from substantive medical changes.
If an article contains an inaccurate medical review credit or clinical statement, use Contact EDMedix to identify the exact page and a verifiable source. We welcome appropriately documented corrections.
No website review constitutes personal clinical care. Questions about your own symptoms, dose or treatment choice require a licensed healthcare professional; emergencies require immediate medical attention.